Insiders who reported open-market trades in the last 12 months at the companies Vimal Mehta files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
Vimal Mehta is a corporate insider, tracked as CEO and President, Director of BioXcel Therapeutics, Inc. (BTAI). InsiderAlpha holds 8 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
When did Vimal Mehta last file a Form 4?
The most recent primary Form 4 on record is dated 18 June 2026, one of 8 filings going back to 2024.
Has Vimal Mehta been buying or selling stock?
Recorded transactions: 0 open-market purchases and 3 open-market sales ($22K) across all tracked filings.
Vimal Mehta is CEO and President, Director of BioXcel Therapeutics, Inc. (BTAI). 8 SEC Form 4 filings on record going back to 2024, most recently on 18 June 2026. Most recent open-market trade: sold $21K of BTAI on 22 May 2026. Lifetime open-market sales: $22K.
Recent transactions
13
The latest 13 SEC Form 4 transactions reported by Vimal Mehta.
InsiderAlpha's records for Vimal Mehta go back to 2024: 8 primary Form 4 filings, an average of 2.7 per year. 9 recorded transactions carry a Rule 10b5-1 plan flag. This identifies the marked transactions as reported under a trading plan; it does not establish the plan status of unmarked transactions.
